Oriental Aromatics Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Recovery taking shape, but patience required: Sales volume grew 4% YoY and EBITDA margin improved sequentially to 8.03%, yet the Mahad facility ramp-up will keep margins in the guided 8–10% band for a few more quarters.
• The "perfect storm" has passed: All three divisions (camphor, fragrance, aroma ingredients) are now contributing positively after a multi-year investment cycle, camphor price erosion, and new capacity entrants compressed margins through FY24.
• Mahad is the swing factor: The multi-purpose plant is running at 20–30% utilization with product sampling underway; management targets 75–80% utilization by year-end, but commercial timelines depend on a 5–6 month customer approval cycle.
• Tariff overhang is real but contained: A new 50% tariff on certain Indian export categories creates near-term uncertainty, though US exposure is "not very substantial" and the company is already working on alternate market channels and supply chain adjustments.
• What to watch next quarter: Whether Mahad commercial shipments begin converting samples into orders, the trajectory of camphor pricing as festive demand kicks in, and any clarity on tariff impact and mitigation.

The Recovery: What Broke and What Is Healing

• FY21–FY24: a triple hit. An R&D and specialty ingredients investment program that began in 2019 continued through ~2023 without economies of scale on sales, coinciding with a sudden camphor price reduction and new capacity entrants, producing a substantial profit margin compression.
• FY25: three tailwinds converged. Camphor-side actions to enforce competitive moat (formulation changes, higher pharma camphor contribution), fragrance division benefiting from backward integration and winning more profitable business, and all aroma ingredient launches except Evermoss crossing the critical 500–600 day product approval and commercial order cycle.
• Q1 FY26: normalization underway. Production volume rose 10% YoY despite a planned maintenance shutdown at Bareilly, sales volume grew 4% YoY, and demand is now normalizing after several quarters of global instability, delays and overstocking.
• Customer base holding firm. All product categories continue to show growth and the customer base remains loyal.

Parag Satoskar: "every single significant consumer of aroma ingredients in the world today, and I can very proudly say that, is buying, if not multiples of 10, but at least 1 product from us."

Mahad Facility: The Next Leg of Growth

• Phase 1 complete, initial sales started. The single-product plant is now commissioned and ramping up production, with initial sales contribution recorded this quarter.
• The approval cycle dictates the pace. A 5–6 month window is required for sampling, customer approvals and then commercial shipments, so revenue contribution will build gradually.
• Current utilization is 20–30%. Management's objective is to reach 75–80% capacity utilization, similar to other plants, by the end of the year.
• Internal validation de-risks external acceptance. The company's own fragrance division, described as its "severest customer," has approved Mahad product, giving management confidence in global customer acceptance.
• Margin trajectory is a two-step process. First, reach optimum utilization; then, through internal process reengineering and offering a globally stable product, achieve eventual margin goals, though whether that lands at 14%, 12% or 10% will be determined by market forces.
• The margin drag is acknowledged. The initial ramp-up phase is expected to continue impacting margins for a few quarters ahead.

Parag Satoskar: "I have the most severest of my customer, which is my internal fragrance division. I mean, if they approve a product, then we are very confident that as we reach out to our global customers, we should not have a problem."

Camphor: Pricing, Mix and Competitive Moat

• Pricing is gradually hardening. Raw material prices are at elevated levels and FOREX impact is also a factor, with camphor prices trending upward over the past few months.
• Formulated camphor dominates the mix. 60% of camphor remains in the formulated space, with the remainder split between exports and pharma; formulated camphor carries a slightly better margin than powdered.
• Feedstock secured for the festive cycle. The company has secured adequate feedstock well ahead of the festive production cycle and aims to capture peak seasonal demand with value-based pricing.
• Competitive moat reinforced through formulation. Actions taken on the camphor side include formulation changes and increasing the contribution of pharma-grade camphor.
• Management declined to provide per-kg pricing. When pressed, a broad range of ₹450–₹550 was offered but qualified as customer-centric and driven by multiple factors.

Fragrance and Aroma Ingredients: Building the Pipeline

• Fragrance division is locking in festive demand. The company is securing briefs from national and regional brands ahead of the festive season while safeguarding large accounts; international fragrance demand remains strong.
• Backward integration is a structural advantage. The Ambernath compounding facility benefits from backward integration into aroma ingredients, an advantage unavailable to most other fragrance companies, and the business was acquired based on expected profitability rather than by reducing margin or extending credit.
• Evermoss is gaining traction. Growing acceptance by the global customer community is underway, though it is the one aroma ingredient launch still working through the approval cycle.
• 40+ products launched, all globally accepted. Every product launched over the last five years has achieved global acceptance, with plants now running at 70–80% capacity.
• No interest in CDMO/CMO tie-ups. Management explicitly declined the idea of partnering with F&O MNCs for contract development or manufacturing, citing a philosophy of "freedom to operate" given the company's position in the generic space.

Dharmil Bodani: "And we are a company that believes a lot in freedom to operate, especially because we are in the generic space. So, it is going to stay that way."

Tariffs, Trade and Risk Management

• A new 50% tariff on certain Indian export categories has created near-term uncertainty. The company is monitoring the situation, evaluating alternate market channels, making supply chain adjustments and engaging in customer-site negotiations.
• US exposure is manageable. Management declined to quantify the percentage of international business going to the US but stated it is "not very substantial to have large impact on immediate basis."
• Contingency planning is underway. Possibilities include earmarking materials for other markets if needed, though the approach remains wait-and-watch.

Shyamal Bodani: "Challenges are inevitable in global business, but it is how we anticipate, adapt and act that defines our trajectory. Oriental Aromatics has navigated demand cycles, currency fluctuations and input cost spikes and each time we have emerged stronger."

Capital Allocation and Capacity

• CAPEX is on pause. Management is going slow, evaluating all CAPEX done and taking it to logical conclusion; nothing is on or off the table, and the company remains open to opportunities from its creative team or global customer interactions.
• Balance sheet capacity exists. Both the balance sheet and P&L have leverage, and land and environmental clearance are available for investments if needed.
• CAPEX optimization already executed. When output pricing challenges were realized, the company entered "massive optimization mode" at the Baroda facility, shaving off certain scheduled CAPEX by finding optimized ways within the current site; at Mahad, one optimization idea has been implemented and another is still being evaluated.
• Hydrogenation plant complete. The brownfield project at the Baroda site is finished and incremental output is already contributing.
• Capacity utilization snapshot. All plants except Mahad are at 75–80% of peak; Ambernath fragrance compounding is on one shift with the ability to add a second shift.
• Incremental sales from capex. On a conservative basis, the ~₹200 crore investment is expected to generate incremental sales of 1.7x over a period of 2 to 3 years.

Guidance & Commitments

Key Metrics